Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
OX40/TNFRSF4 Antibody (7D6), DyLight 755

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB10064375IR
Description
OX40/TNFRSF4 Monoclonal specifically detects OX40/TNFRSF4 in Feline samples. It is validated for Western Blot, Flow Cytometry.Specifications
OX40/TNFRSF4 | |
Monoclonal | |
DyLight 755 | |
ACT35 antigen, ACT35ATC35 antigen, CD134, CD134 antigen, OX40 cell surface antigen, OX40 homologue, OX40L receptor, OX40lymphoid activation antigene ACT35, TAX transcriptionally-activated glycoprotein 1 receptor, tax-transcriptionally activated glycoprotein 1 receptor, tumor necrosis factor receptor superfamily member 4, tumor necrosis factor receptor superfamily, member 4, TXGP1LOX40 antigen | |
Mouse | |
Protein A purified | |
RUO | |
Primary | |
NB100-64375 recognizes feline CD134, otherwise known as OX40, a 43kDa type I membrane protein and member of the tumor necrosis factor receptor superfamily, expressed predominantly by CD4+ activated T cells, and a key regulator of T cell-dependent immune responses. CD134 has been identified as the receptor for the OX40 ligand, CD252, expressed by activated B cells, acting as a co-stimulatory signal for the stimulation and secretion of immunoglobulins. CD134 has also been identified as a binding receptor for Feline Immunodeficiency Virus (FIV), acting along with CXC chemokine receptor 4 (CXCR4) to facilitate the entry of the virus into CD4+ primary target cells. | |
Store at 4C in the dark. | |
IgG1 |
Western Blot, Flow Cytometry | |
7D6 | |
Western Blot, Flow Cytometry | |
TNFRSF4 | |
CHO-derived feline CD134-Fc fusion protein. | |
0.1 mL | |
Cancer, Cell Cycle and Replication, Immunology | |
7293 | |
Feline | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction